JAK3 mutation
|
NSCLC
|
JAK3 mutation
|
NSCLC
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
JAK3 mutation
|
Prolymphocytic Leukemia
|
JAK3 mutation
|
Prolymphocytic Leukemia
|
venetoclax + ruxolitinib Sensitive: C3 – Early Trials
|
venetoclax + ruxolitinib Sensitive: C3 – Early Trials
|
JAK3 mutation
|
T Acute Lymphoblastic Leukemia
|
JAK3 mutation
|
T Acute Lymphoblastic Leukemia
|
tofacitinib Resistant: C4 – Case Studies
|
tofacitinib Resistant: C4 – Case Studies
|